Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trimodulin versus placebo in mechanically ventilated adults with severe community-acquired pneumonia
MOH_2024-01-03_013157Phase 3Recruiting
- Sponsor
- Biotest AG
- Start
- Jul 2023
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in community-acquired pneumonia (CAP) comparing Trimodulin + standard of care with Placebo + standard of care (2 arms). Primary endpoint: All-cause mortality through Day 28. Started Jul 2023; status: recruiting.
02
Drugs
Pentaglobin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on MOH_2024-01-03_013157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-03_013157.